Arcus Biosciences Inc. (RCUS) announced on Sunday, 13 October 2025, that the first overall survival data from Arm A1 of its Phase 2 EDGE‑Gastric study have been released. The study evaluated the combination of the Fc‑silent anti‑TIGIT antibody domvanalimab, the anti‑PD‑1 antibody zimberelimab, and standard chemotherapy in patients with locally advanced, unresectable, or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma.
The data show a median overall survival of 26.7 months (90 % CI 18.4–NE) and a confirmed objective response rate of 59 % (95 % CI 45–72 %). Median progression‑free survival was 12.9 months (90 % CI 9.8–14.6). No unexpected safety signals were observed, and the regimen was generally well tolerated, with immune‑mediated adverse events in 22 % of patients and infusion‑related reactions in 7 %.
These results represent a significant clinical benefit over standard of care and support the continued development of domvanalimab in combination with zimberelimab. The company will present the data at the ESMO 2025 Congress, and the findings reinforce confidence in the ongoing Phase 3 STAR‑221 study, which is enrolling patients with the same indication.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.